A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : RZV / recombinant zoster vaccine

[Related PubMed/MEDLINE]
Total Number of Papers: 41
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   RZV  (>> Co-occurring Abbreviation)
Long Form:   recombinant zoster vaccine
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A systematic literature review of the recombinant subunit herpes zoster vaccine use in immunocompromised 18-49year old patients. HZ, PRISMA-P, SAEs
2020 Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials. HZ, pIMDs, SAEs
2020 Emerging Topics in Vaccine Therapeutics for Adolescents and Adults: An Update for Immunizing Pharmacists. CDC/ACIP, FDA, HPV, MMR
2020 Exploring the early phase of implementation of a vaccine-based clinical decision support system in the community pharmacy. CDS
2020 Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial. AEs, gE, pIMDs, RT
2020 Immunogenicity of the adjuvanted recombinant zoster vaccine: persistence and anamnestic response to additional doses administered 10 years after primary vaccination. CMI
2020 Impact of pharmacist intervention on completion of recombinant zoster vaccine series in a community pharmacy. OR
2020 Impact of Reactogenicity After Two Doses of Recombinant Zoster Vaccine Upon Physical Functioning and Quality of Life: An Open Phase III Trial in Older Adults. EQ-5D, PF, QOL, SF-36
2020 Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model. BI, HZ, IDN, PBDMs, ZVL
10  2020 Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials. AEs
11  2020 Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology. HZ
12  2020 Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine. AE, O/E
13  2020 The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine. CMI, gE, HZ
14  2020 The potential public health impact of Herpes Zoster vaccination in the 65 years of age cohort in Italy. HZ, PHN, ZVL
15  2019 A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations. ICER, QALY, ZVL
16  2019 Clarification regarding the statement of the association between the recombinant zoster vaccine (RZV) and gout flares. ---
17  2019 Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live. QALYs, ZONA, ZVL
18  2019 Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan. HZ, ICERs, VVL, VVL
19  2019 Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65Years and Older. HZ, ICER, PHN, QALYs
20  2019 Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials. HZ, PHN
21  2019 Evaluation of two frailty indices, with practical application in a vaccine clinical trial. FIs, PF, PROs, SF-36
22  2019 Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial. AEs, gE, STs, VRRs
23  2019 Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials. CI, HZ
24  2019 Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) - United States, October 2017-June 2018. FDA, VAERS
25  2019 Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults. HZ, ICER, PHN, QALY
26  2019 Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme. HZ, PHI, PHN, YOA, ZVL
27  2019 Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT). CI, HSCT, HZ, QOL, VE, ZBPI
28  2019 Response to: 'Clarification regarding the statement of the association between the recombinant zoster vaccine (RZV) and gout flares' by Didierlaurent et al. ---
29  2019 Risk of gout flares after vaccination: a prospective case cross-over study. ---
30  2019 Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials. AEs, pIMDs, SAEs
31  2019 The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged ≥50 years: A randomized trial. Tdap, VRR
32  2019 The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis. HZ, NMA, PHN, SAE, VE, ZVL
33  2019 The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial. ---
34  2019 Vaccines for preventing herpes zoster in older adults. CI, LZV, NNTB, NNTH, RCTs, RD, RR, VZV
35  2019 Varicella zoster virus vaccines: an update. ACIP, CMI, HZ, VZV, ZVL
36  2018 Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States. HZ, PHN, YOA, ZVL
37  2018 Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial. VRR
38  2018 Primary care physicians' experience with zoster vaccine live (ZVL) and awareness and attitudes regarding the new recombinant zoster vaccine (RZV). ACIP, ZVL
39  2018 Recombinant Zoster Vaccine (Shingrix): A Review in Herpes Zoster. HZ, PHN
40  2018 Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. ACIP, GSK
41  2018 The Potential Public Health Impact of Herpes Zoster Vaccination of People Aged ≥ 50Years in Japan: Results of a Markov Model Analysis. HZ, PHN, VVL